Timing of renal replacement therapy does not influence survival and growth in children with congenital nephrotic syndrome caused by mutations in NPHS1: data from the ESPN/ERA-EDTA Registry

Holtta, Tuula; Bonthuis, Marjolein; Van Stralen, Karlijn; Bjerre, Anna; TOPALOĞLU, REZAN; ÖZALTIN, FATİH; Holmberg, Christer; Harambat, Jerome; Jager, Kitty; Schaefer, Franz; Groothoff, Jaap

doi:10.1007/s00467-016-3517-z

Timing of renal replacement therapy does not influence survival and growth in children with congenital nephrotic syndrome caused by mutations in NPHS1: data from the ESPN/ERA-EDTA Registry

Atıf İçin Kopyala

Holtta T., Bonthuis M., Van Stralen K. J., Bjerre A., TOPALOĞLU R., ÖZALTIN F., ...Daha Fazla

PEDIATRIC NEPHROLOGY, cilt.31, sa.12, ss.2317-2325, 2016 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 31 Sayı: 12
Basım Tarihi: 2016
Doi Numarası: 10.1007/s00467-016-3517-z
Dergi Adı: PEDIATRIC NEPHROLOGY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.2317-2325
Anahtar Kelimeler: Congenital nephrotic syndrome, NPHS1, Kidney transplantation, Graft survival, Dialysis, Pediatrics, PERITONEAL-DIALYSIS, GLOMERULAR PROTEIN, 1ST YEAR, EXPERIENCE, MANAGEMENT, TRANSPLANTATION, INFANTS, NEPHRIN, EUROPE, LIFE
Hacettepe Üniversitesi Adresli: Evet

Özet

Congenital nephrotic syndrome (CNS) of the Finnish type, NPHS1, is the most severe form of CNS. Outcomes of renal replacement therapy (RRT) in NPHS1 patients in Europe were analysed using data from the ESPN/ERA-EDTA Registry. As NPHS1 is most prevalent in Finland and the therapeutic approach differs from that in many other countries, we compared outcomes in Finnish and other European patients.